APGE Apogee Therapeutics, Inc. Common Stock Loading...

From ABBV earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
13:00
Jul 31 ◎
Rob Michael Chairman and Chief Executive Officer, AbbVie Inc. ABBV Q2 FY26 call
Acquisition target that AbbVie believes holds significant long-term potential in dermatology, respiratory, and other inflammatory diseases.
APGE
HIGH

About APGE Analyst Coverage

Buzzberg tracks APGE (Apogee Therapeutics, Inc. Common Stock) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Latest voices: Rob Michael.